(Total Views: 1483)
Posted On: 03/22/2018 8:04:32 AM
Post# of 4528
$AYTU ** OFFICIAL DUE DILIGENCE THREAD **
1) The offering is for 26,666,667 total commons at .45 - and right to purchase 26,666,667 warrants at .54
2) The warrants mean the holders have a right to purchase shares at .54 to sell them higher inorder to profit.
3) AYTU revenues increased by about 1 million from 2016 to 2017. Lead product is NATESTO , an already FDA approved TRT medication.
4) NATESTO offers many advantages over current TRT drugs. As of 2017, if we penetrate 5% of market that is annual revs of ~100M !!
5) Biggest competitor Androgel patent expired and is now facing competition from generics. NATESTO offers many advantages over Androgel.
6) In addition to its safety profile NATESTO has no black box warning from FDA and is convenient , administered nasally.
7) AYTU also has other products, in particular Mioxsys a rapid fertility test , up for potential FDA approval in the future.
AYTU OS will be in the low 30Ms excluding any warrants. This accounts for preferreds in recent offering. AYTU now has significant cash.
9) NATESTO is seeing exponential growth in US
10) AYTU Insiders have bought significant amount of shares at .45 - See attachment.
11) The reason for including preferreds in offering is so certain institutions wont have more than 4.99% of commons at once.
12) Our CEO saw his previous company, Arbor Pharma, go without revenues to 120m in under 4 years time ! He was VP of Arbor.
13) AYTU uplisted to Nasdaq only last year, now full with cash and increasing NATESTO sales, I'm expecting several exciting catalysts ahead
14) If all warrants were exercised above .54 the company would receive 14M dollars in addition to the cash they have now!!
The above from @pennygodfather Disclosure : Not investment advice. I currently hold shares of $AYTU and may buy or sell anytime
Marketed Products
Aytu products at a glance
NATESTO® (testosterone) nasal gel, the only FDA-approved nasally administered testosterone indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism.
THE MiOXSYS® SYSTEM A novel, rapid in vitro diagnostic semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility.
PROSTASCINT® (capromab pendetide), the only radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.
AYTU WOMEN’S HEALTH is focused on improving personal health and sexual wellness for women, and currently markets Fiera®. Fiera is the first of its kind, hands-free, personal care device for women, that enhances physical arousal and interest in sex.
Chart Analysis
1) The offering is for 26,666,667 total commons at .45 - and right to purchase 26,666,667 warrants at .54
2) The warrants mean the holders have a right to purchase shares at .54 to sell them higher inorder to profit.
3) AYTU revenues increased by about 1 million from 2016 to 2017. Lead product is NATESTO , an already FDA approved TRT medication.
4) NATESTO offers many advantages over current TRT drugs. As of 2017, if we penetrate 5% of market that is annual revs of ~100M !!
5) Biggest competitor Androgel patent expired and is now facing competition from generics. NATESTO offers many advantages over Androgel.
6) In addition to its safety profile NATESTO has no black box warning from FDA and is convenient , administered nasally.
7) AYTU also has other products, in particular Mioxsys a rapid fertility test , up for potential FDA approval in the future.
AYTU OS will be in the low 30Ms excluding any warrants. This accounts for preferreds in recent offering. AYTU now has significant cash. 9) NATESTO is seeing exponential growth in US
10) AYTU Insiders have bought significant amount of shares at .45 - See attachment.
11) The reason for including preferreds in offering is so certain institutions wont have more than 4.99% of commons at once.
12) Our CEO saw his previous company, Arbor Pharma, go without revenues to 120m in under 4 years time ! He was VP of Arbor.
13) AYTU uplisted to Nasdaq only last year, now full with cash and increasing NATESTO sales, I'm expecting several exciting catalysts ahead
14) If all warrants were exercised above .54 the company would receive 14M dollars in addition to the cash they have now!!
The above from @pennygodfather Disclosure : Not investment advice. I currently hold shares of $AYTU and may buy or sell anytime
Marketed Products
Aytu products at a glance
NATESTO® (testosterone) nasal gel, the only FDA-approved nasally administered testosterone indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism.
THE MiOXSYS® SYSTEM A novel, rapid in vitro diagnostic semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility.
PROSTASCINT® (capromab pendetide), the only radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.
AYTU WOMEN’S HEALTH is focused on improving personal health and sexual wellness for women, and currently markets Fiera®. Fiera is the first of its kind, hands-free, personal care device for women, that enhances physical arousal and interest in sex.
Chart Analysis
(3)
(0) Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
